share_log

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

Aurora Cannabis | 6-K: Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility

極光大麻 | 6-K:極光大麻獲得德國工廠擴大種植和獨特研究許可
美股SEC公告 ·  2024/07/27 02:21

Moomoo AI 已提取核心訊息

Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Aurora views these developments as part of a broader trend towards medical cannabis acceptance in Europe. The company's President for Europe, Michael Simon, emphasized Aurora's established leadership in the region and their ability to leverage global cultivation expertise locally. Aurora aims to extend its portfolio and invest in domestic research, supporting Germany's efforts to improve patient access to medical cannabis.
Aurora Cannabis Inc. has been granted two licenses by Germany's Federal Institute for Drugs and Medical Devices under the new Medical Cannabis Act. The expanded cultivation license allows Aurora to continue domestic production and add an approved product, while a dedicated R&D license permits trials of up to seven novel cultivars at their EU GMP facility in Leuna.Since 2021, Aurora's Leuna facility has been producing approximately 1,000 kg of medical cannabis flower annually under a tender agreement. The new licenses reflect Aurora's commitment to quality and compliance, positioning the company to meet growing patient demand in Germany's expanding medical cannabis market.Aurora views these developments as part of a broader trend towards medical cannabis acceptance in Europe. The company's President for Europe, Michael Simon, emphasized Aurora's established leadership in the region and their ability to leverage global cultivation expertise locally. Aurora aims to extend its portfolio and invest in domestic research, supporting Germany's efforts to improve patient access to medical cannabis.
Aurora 大麻股公司已獲得德國聯邦藥品和醫療設備研究所根據新醫療大麻法案頒發的兩項許可證。擴展種植許可證允許Aurora繼續國內生產並增加一種已批准的產品,而專門的研發許可證則允許在他們位於萊烏納的EU GMP設施中進行多達七種新種植品種的試驗。自2021年以來,Aurora的萊烏納設施每年在投標協議下生產約1000公斤的醫療大麻花。新許可證反映了Aurora對質量和合規性的承諾,使公司能夠滿足德國不斷增長的醫療大麻市場中患者的需求。Aurora視這些發展爲歐洲向醫療大麻接受度更廣泛趨勢的一部分。公司的歐洲總裁邁克爾·西蒙強調了Aurora在這一地域板塊中的領導地位以及他們在當地利用全球種植專業知識的能力。Aurora旨在擴展其產品組合並投資於國內研究,支持德國改善患者對醫療大麻的獲取。
Aurora 大麻股公司已獲得德國聯邦藥品和醫療設備研究所根據新醫療大麻法案頒發的兩項許可證。擴展種植許可證允許Aurora繼續國內生產並增加一種已批准的產品,而專門的研發許可證則允許在他們位於萊烏納的EU GMP設施中進行多達七種新種植品種的試驗。自2021年以來,Aurora的萊烏納設施每年在投標協議下生產約1000公斤的醫療大麻花。新許可證反映了Aurora對質量和合規性的承諾,使公司能夠滿足德國不斷增長的醫療大麻市場中患者的需求。Aurora視這些發展爲歐洲向醫療大麻接受度更廣泛趨勢的一部分。公司的歐洲總裁邁克爾·西蒙強調了Aurora在這一地域板塊中的領導地位以及他們在當地利用全球種植專業知識的能力。Aurora旨在擴展其產品組合並投資於國內研究,支持德國改善患者對醫療大麻的獲取。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息